StockData
Nuvectis Pharma, Inc. logo

Nuvectis Pharma, Inc. (NVCT) stock

NVCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$19.20+0.09 (+0.47%)

Close on Nov 17, 2026Market cap $625.57MP/E –Yield 0.00%

Nuvectis Pharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Nuvectis Pharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$19.51M. For fiscal 2025 it was -$16.01M. The highest annual figure on record is -$9.50M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$16.01M–
FY2024Dec 31, 2024-$12.25M–
FY2023Dec 31, 2023-$15.95M–
FY2022Dec 31, 2022-$13.56M–
FY2021Dec 31, 2021-$9.50M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.53M–
Q1 FY2026Mar 31, 2026-$6.51M–
Q4 FY2025Dec 31, 2025-$3.97M–
Q3 FY2025Sep 30, 2025-$4.49M–
Q2 FY2025Jun 30, 2025-$3.37M–
Q1 FY2025Mar 31, 2025-$4.17M–
Q4 FY2024Dec 31, 2024-$2.47M–
Q3 FY2024Sep 30, 2024-$2.40M–
Q2 FY2024Jun 30, 2024-$3.02M–
Q1 FY2024Mar 31, 2024-$4.36M–
Q4 FY2023Dec 31, 2023-$3.85M–
Q3 FY2023Sep 30, 2023-$3.24M–
Q2 FY2023Jun 30, 2023-$4.08M–
Q1 FY2023Mar 31, 2023-$4.78M–
Q4 FY2022Dec 31, 2022-$3.52M–
Q3 FY2022Sep 30, 2022-$4.42M–
Q2 FY2022Jun 30, 2022-$2.54M–
Q1 FY2022Mar 31, 2022-$3.08M–
Q4 FY2021Dec 31, 2021-$1.07M–
Q3 FY2021Sep 30, 2021-$4.43M–

More Nuvectis Pharma figures

See a number that looks wrong?